Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

PTN Palatin Technologies Inc New

0.04 (2.04%)
Nov 30 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 27,796
Bid Price
Ask Price
News -
Day High 2.00


52 Week Range


Day Low 1.95
Company Name Stock Ticker Symbol Market Type
Palatin Technologies Inc New PTN AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.04 2.04% 2.00 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.99 1.95 2.00 2.00 1.96
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
265 27,796 $ 1.98 $ 54,941 - 1.43 - 5.00
Last Trade Time Type Quantity Stock Price Currency
20:00:00 514 $ 2.00 USD

Palatin Technologies Inc New Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
27.47M 13.74M - 5.88M -27.54M -2.00 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Palatin Technologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No PTN Message Board. Create One! See More Posts on PTN Message Board See More Message Board Posts

Historical PTN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.002.051.861.9561,6070.000.0%
1 Month2.112.27781.811.9967,761-0.11-5.21%
3 Months2.292.601.431.95121,343-0.29-12.66%
6 Months2.553.271.432.1396,870-0.55-21.57%
1 Year3.785.001.432.5186,436-1.78-47.09%
3 Years0.458.600.18110.72496621,942,1341.55344.44%
5 Years0.818.600.18110.76463531,842,8831.19146.91%

Palatin Technologies Description

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Your Recent History

Delayed Upgrade Clock